Iloprost Drugs Market - Inhaled iloprost for the treatment of pulmonary hypertension
Global Iloprost Drugs Market Analysis
Overview
Iloprost is a medication used to treat disorders like pulmonary arterial hypertension, scleroderma, Raynaud syndrome, and other disorders that cause blood vessel constriction and poor blood flow in tissues. The drug's brand name is Ventavis or Ilomedine. Iloprost was approved by the US Food and Drug Administration. In 2004, the Food and Drug Administration (FDA) approved a treatment for pulmonary arterial hypertension.
Iloprost dilates the compressed blood vessels in the lungs, lowering heart rate and lowering pulmonary blood pressure. The medicine may be given as an injection or inhaled by nebulizers. The injection is given intravenously and lasts approximately six hours a day; the session is performed three to five days in a row, while the inhalations can be conducted six to nine times a day, as directed by the physician.
Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/3284
Drivers
Over the forecast period, the high incidence of pulmonary arterial hypertension is expected to drive growth of the global iloprost drugs market during the forecast period. About 500 to 1000 new cases of pulmonary arterial hypertension are diagnosed per year in the U.S., according to the NORD (National Organization for Rare Disorders).
Furthermore, a number of big company mergers, partnerships, and acquisitions are expected to propel growth of the global iloprost drugs market over the forecast period. Johnson & Johnson announced in January 2017 that it would acquire Acetlion, including its branded brands in the pulmonary arterial hypertension franchise.
Furthermore, a growing number of players are focused on developing this drug in order to, which is stimulating growth of the global iloprost drugs market over the forecast period. Globally, about 15 clinical trials involving Iloprost were successful in 2018, according to the National Institute of Health. The National Cancer Institute started a phase I clinical trial in November 2015 to see whether iloprost would prevent lung cancer recurrence in smokers, and the research is scheduled to finish in 2020.
Tailored Information as per niche requirement:
LIMITED TIME OFFER - Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/3284
Restraint
However, the medication can cause kidney dysfunction, dyspnea, chest pain, shortness of breath, and limb swelling. Over the forecast period, the above-mentioned side effects are expected to limit the growth of the global iloprost drugs market.
Regional Analysis
Due to mergers, partnerships, and acquisitions by major players in the region, North America had the largest market share in 2018. In August 2019, Bayer AG granted VisionGate, a California-based oncology pharmaceutical and diagnostics corporation, an exclusive worldwide right and license to produce, make, sell, and market iloprost betadex clathrate in the area of lung cancer care and prevention. In addition, Bayer AG and Vectura partnered in 2012 to create Breelib, a hand-held nebulizer system intended to increase the delivery of Bayer's Ventavis (iloprost).
To get detailed table of content (ToC), please click - https://www.coherentmarketinsights.com/ongoing-insight/toc/3284
Competitive Landscape
VisionGate, Bayer AG, Actelion Pharmaceuticals, and Vectura Group Plc. are among the leading manufacturers in the global iloprost drugs market. Furthermore, leading brands are concentrating on creating new goods in order to increase their market share. Vectura Group Plc was acquired by Bayer AG in 2017. Their partnership has been expanded once more to produce an improved version of the nebulizer Breelib, which increases the effectiveness of iloprost aerosol therapy in patients with pulmonary atrial hypertension. The nebulizer is currently in a clinical trial, according to the National Institute of Health, with the testing set to end in March 2020.
Table of Content
Global Iloprost Drugs Market Research Report
Section 1: Global Iloprost Drugs Industry Overview
Section 2: Global Economic Impact on Iloprost Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Iloprost Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Iloprost Drugs Market Forecast
Other Exclusive Reports:
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- Coherent Market Insights
-
Name:
- Nirav Gokani
- Email:
-
Telephone:
- +918849480752
- Website:
Related Links
- Website: Iloprost Drugs Market
